Dengue Hemorrhagic Fever (DHF)
Overview
Dengue hemorrhagic fever (DHF) is a severe, potentially life‑threatening complication of infection with any of the four dengue virus serotypes (DENV‑1 to DENV‑4). It is characterized by high fever, bleeding tendencies, low platelet counts, and plasma leakage that can lead to shock.
Although the disease can affect anyone, children and adolescents in endemic regions are most frequently reported, and prior infection with a different dengue serotype markedly increases the risk of DHF.
According to the World Health Organization (WHO), an estimated 390 million dengue infections occur worldwide each year, with 500 000 cases progressing to severe dengue (including DHF) and ~25 000 deaths annually.WHO Dengue is endemic in more than 100 countries, primarily in Southeast Asia, the Western Pacific, the Americas, and Africa.
Symptoms
Symptoms of DHF usually appear 3–7 days after the initial dengue fever phase (the “critical phase”).
- High fever (≥38.5 °C/101.3 °F) lasting 2–7 days.
- Severe headache and retro‑orbital (behind the eyes) pain.
- Muscle and joint pain – classic “break‑bone” pain.
- Persistent vomiting or nausea.
- Rash – often appears 3–5 days after fever onset; may be maculopapular or petechial.
- Bleeding manifestations (the hallmark of DHF):
- Gum bleeding, nosebleeds (epistaxis), or easy bruising.
- Positive tourniquet test (tiny red spots called petechiae).
- Hematuria (blood in urine) or melena (black, tarry stools).
- Abdominal pain or tenderness, especially in the right upper quadrant.
- Rapid, weak pulse & low blood pressure** – indicating plasma leakage and possible shock.
- Reduced urine output** (oliguria) or dark‑colored urine.
- Elevated hematocrit (percentage of red blood cells) with falling platelet count.
Symptoms are classified into four phases:
- Febrile phase – high fever, typical dengue symptoms.
- Critical phase (24–48 h after fever drops) – plasma leakage, bleeding, shock risk.
- Recovery phase – reabsorption of leaked fluid, platelet count rises.
- Convalescent phase – gradual return to baseline health.
Causes and Risk Factors
What Causes DHF?
Dengue viruses are transmitted primarily by the bite of infected Aedes aegypti and Aedes albopictus mosquitoes. Once inside the human host, the virus replicates in dendritic cells, monocytes, and endothelial cells, triggering an intense immune response.
Severe disease (DHF) is believed to result from:
- Antibody‑Dependent Enhancement (ADE) – non‑neutralizing antibodies from a previous dengue infection bind to a new serotype, facilitating viral entry into host cells and amplifying cytokine release.
- Host genetic factors – certain HLA types and cytokine gene polymorphisms increase susceptibility.
- High viral load and virulent virus strains.
Who Is at Higher Risk?
- Individuals with a **secondary infection** by a different serotype (most common cause of DHF).
- Children and adolescents (< 15 years) in endemic areas.
- People with **pre‑existing comorbidities** such as asthma, diabetes, or cardiovascular disease.
- Pregnant women – infection can increase risk of hemorrhage and adverse fetal outcomes.
- Residents of **urban slums** where Aedes breeding sites (e.g., water containers) are abundant.
Diagnosis
Accurate and timely diagnosis is essential because the clinical course can deteriorate rapidly.
Clinical Evaluation
- History of recent travel to dengue‑endemic region or known local outbreak.
- Physical exam focusing on fever, rash, bleeding signs, and signs of plasma leakage (e.g., pleural effusion, ascites).
- Monitoring vital signs for tachycardia, hypotension, or narrow pulse pressure.
Laboratory Tests
| Test | Purpose | Typical Findings in DHF |
|---|---|---|
| Complete Blood Count (CBC) | Assess platelets, hematocrit, white cells | Platelet count <150 × 10⁹/L; rising hematocrit >20% from baseline |
| Serum Electrolytes & Creatinine | Detect organ dysfunction | Potential rise in creatinine indicating kidney involvement |
| Coagulation Profile (PT/INR, aPTT) | Evaluate bleeding risk | May be prolonged in severe cases |
| Dengue NS1 Antigen Test | Detect viral protein early (days 1‑5) | Positive in acute infection |
| RT‑PCR for Dengue RNA | Confirm serotype, high sensitivity | Positive during first 5 days |
| IgM/IgG ELISA | Serology after day 5 | IgM positive in primary infection; high IgG titers in secondary infection (risk for DHF) |
| Ultrasound (abdomen, chest) | Detect plasma leakage (pleural effusion, ascites) | Positive findings support DHF diagnosis |
WHO criteria for DHF require all four of the following:
- Fever lasting 2–7 days.
- Hemorrhagic tendencies demonstrated by a positive tourniquet test or spontaneous bleeding.
- Platelet count ≤100 × 10⁹/L.
- Evidence of plasma leakage (hematocrit rise ≥20% or pleural effusion/ascites).CDC
Treatment Options
There is no specific antiviral drug for dengue; management focuses on supportive care and careful monitoring.
Fluid Management
- Oral rehydration during febrile phase if tolerated.
- Intravenous isotonic crystalloids (e.g., Ringer’s lactate) for patients entering the critical phase or showing signs of plasma leakage, hypotension, or oliguria.
- Goal: maintain a **hematocrit** that is stable or slowly decreasing and a **urine output** ≥0.5 mL/kg/h.
Medication
- Pain & fever – acetaminophen (paracetamol) 500‑1000 mg every 6 h, max 4 g/day. Avoid NSAIDs** (ibuprofen, aspirin) because they increase bleeding risk.
- Blood products – platelet transfusion if count <20 × 10⁹/L with active bleeding; packed red cells for severe hemorrhage or shock.
- Corticosteroids – not routinely recommended; may be considered in severe immune‑mediated complications under specialist guidance.
Monitoring & Hospitalization
Patients with suspected DHF should be admitted to a monitored bed (often a step‑down or intensive care unit) for at least 48–72 hours to watch for rapid changes in vital signs, hematocrit, and platelet trends.
Lifestyle and Supportive Measures
- Bed rest during the critical phase.
- Frequent temperature checks.
- Balanced diet with adequate protein; avoid heavy, fatty meals that may cause nausea.
- Close observation of urine color and volume.
Living with Dengue Hemorrhagic Fever
Even after discharge, patients may need to manage lingering fatigue and watch for delayed complications.
Post‑recovery Tips
- Gradual return to activity – begin with light tasks after 1 week; full activity after hematologic parameters normalize.
- Nutrition – iron‑rich foods (leafy greens, legumes) and vitamin C to aid platelet recovery.
- Hydration – continue drinking water, oral rehydration solutions, or clear soups for at least 2 weeks.
- Follow‑up appointments – repeat CBC at 1 week and 1 month to ensure platelet and hematocrit stability.
- Psychological support – anxiety about future infections is common; counseling or support groups can help.
Prevention
Because there is no cure, preventing infection and mosquito exposure is paramount.
Vector Control
- Eliminate standing water (flower pots, tires, buckets) every 2–3 days.
- Use larvicides (e.g., Bacillus thuringiensis israelensis) in water containers that cannot be emptied.
- Screen windows and doors; install fine‑mesh netting.
- Community clean‑up campaigns have reduced dengue incidence by up to 30 % in some Asian cities.CDC
Personal Protection
- Wear long‑sleeved shirts and pants, especially at dawn and dusk.
- Apply EPA‑registered DEET (≥20 %), picaridin, or oil of lemon eucalyptus on exposed skin.
- Sleep under insecticide‑treated bed nets if air‑conditioning is unavailable.
Vaccination
The WHO‑approved tetravalent dengue vaccine (CYD‑TD, brand name Dengvaxia) is licensed for people aged 9–45 years with documented prior dengue infection. It reduces the risk of severe disease by ~79 % in seropositive individuals but may increase risk in seronegative persons, so pre‑vaccination screening is required.WHO
Complications
If DHF is not recognized early or fluid management fails, several life‑threatening complications can develop:
- Dengue shock syndrome (DSS) – severe plasma leakage leading to hypotension and organ hypoperfusion.
- Severe hemorrhage – intracranial, gastrointestinal, or pulmonary bleeding.
- Acute respiratory distress syndrome (ARDS) secondary to pleural effusion or pulmonary hemorrhage.
- Acute kidney injury from hypovolemia.
- Hepatic dysfunction – transaminases may rise > 1000 U/L; rarely fulminant hepatic failure.
- Neurological involvement – encephalitis, seizures, or Guillain‑Barré‑like syndrome.
Mortality rates for untreated DHF can exceed 20 %; with appropriate supportive care, it drops below 1 % in experienced centers.Cleveland Clinic
When to Seek Emergency Care
- Rapid, weak pulse or a drop in blood pressure (feeling faint, dizziness).
- Severe abdominal pain or persistent vomiting.
- Bleeding that does not stop after 10 minutes (nosebleeds, gum bleeding, blood in urine or stool).
- Sudden change in mental status – confusion, lethargy, seizures.
- Rapid breathing or shortness of breath.
- Decreased urine output (less than 400 mL/24 h) or dark, concentrated urine.
- Persistent high fever (>38.5 °C) lasting more than 7 days.
Early treatment can prevent progression to shock and reduce the risk of death.
For any concerns or if you suspect dengue infection, contact your primary care provider promptly. Always follow local public‑health guidance during outbreaks.
Sources: World Health Organization, Centers for Disease Control and Prevention, Mayo Clinic, National Institutes of Health, Cleveland Clinic, peer‑reviewed articles in The Lancet Infectious Diseases and Journal of Virology.
```